Our previous research [16, 17] showed that eIF5A2 enhanced NSCLC cell cisplatin resistance by regulating epithelial-mesenchymal transition (EMT) and modulating NSCLC cell invasion and migration. The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.